Q3 2024 Earnings Forecast for Cingulate Inc. (NASDAQ:CING) Issued By Zacks Small Cap

Cingulate Inc. (NASDAQ:CING) – Stock analysts at Zacks Small Cap issued their Q3 2024 earnings per share estimates for shares of Cingulate in a research note issued to investors on Monday, August 26th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will post earnings of ($3.03) per share for the quarter. Zacks Small Cap also issued estimates for Cingulate’s Q4 2024 earnings at ($3.20) EPS, FY2024 earnings at ($16.00) EPS, FY2025 earnings at ($3.25) EPS and FY2026 earnings at ($0.32) EPS.

Cingulate Stock Performance

Shares of NASDAQ CING opened at $8.00 on Wednesday. The firm has a fifty day simple moving average of $2.50 and a two-hundred day simple moving average of $1.50. Cingulate has a 12 month low of $1.80 and a 12 month high of $187.20.

Cingulate (NASDAQ:CING) last posted its earnings results on Tuesday, August 13th. The company reported ($5.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.64) by $0.17.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cingulate stock. Armistice Capital LLC acquired a new position in Cingulate Inc. (NASDAQ:CING) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 490,000 shares of the company’s stock, valued at approximately $157,000. Armistice Capital LLC owned approximately 6.67% of Cingulate at the end of the most recent quarter. 41.31% of the stock is currently owned by institutional investors.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.